This ADC product is comprised of an anti-EGFR monoclonal antibody (Cetuximab) conjugated via a VC-PAB linker to MODO. The MODO is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MODO binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer. Multiple alternatively spliced transcript variants that encode different protein isoforms have been found for this gene.
Dolastatin is originally isolated from the marine mollusk Dolabella auricularia with potential antineoplastic activity. Binding to tubulin, dolastatin 10 inhibits microtubule assembly, resulting in the formation of tubulin aggregates and inhibition of mitosis. This agent also induces tumor cell apoptosis through a mechanism involving bcl-2, an oncoprotein that is overexpressed in some cancers.